{"transactions":[{"id":741413,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:30:17.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":2.78,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001201256-26-000003","document":"form4-06112026_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120125626000003/form4-06112026_040613.xml","form_type":"4"}},{"id":876967,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:08.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000119312526082815/ownership.xml","form_type":"4"}},{"id":950564,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:05:30.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000006","document":"wk-form4_1767647121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000150169726000006/wk-form4_1767647121.xml","form_type":"4"}},{"id":1116135,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:25:25.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":5555,"source":{"system":"sec-edgar","filing":"0001628280-25-030489","document":"wk-form4_1749587118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828025030489/wk-form4_1749587118.xml","form_type":"4"}},{"id":1168271,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-21T21:15:12.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12000,"derivative":{"exercise_price":17.04,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011110","document":"form4-04212025_050409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000141588925011110/form4-04212025_050409.xml","form_type":"4"}},{"id":1169579,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-17T22:50:16.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":18441,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 137,500 shares of common stock of Tvardi Therapeutics, Inc. (\"Legacy Tvardi\") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\") and Legacy Tvardi, as amended (the \"Merger Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the \"Merger\"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":18441,"derivative":{"exercise_price":4.7,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":18441},"source":{"system":"sec-edgar","filing":"0001415889-25-010982","document":"form4-04172025_060413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000141588925010982/form4-04172025_060413.xml","form_type":"4"}},{"id":1280161,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":30487,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":30487,"derivative":{"underlying":"American Depository Shares","underlying_shares":30487},"source":{"system":"sec-edgar","filing":"0000950170-25-015418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017025015418/ownership.xml","form_type":"4"}},{"id":1280160,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017025015418/ownership.xml","form_type":"4"}},{"id":1477034,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-17T20:15:04.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":25050,"price":3.99,"value":99949.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":25050,"source":{"system":"sec-edgar","filing":"0000950170-24-074248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017024074248/ownership.xml","form_type":"4"}},{"id":1483180,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:12.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":121667,"source":{"system":"sec-edgar","filing":"0001628280-24-027671","document":"wk-form4_1718136724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828024027671/wk-form4_1718136724.xml","form_type":"4"}},{"id":1651376,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2024-02-09T21:15:20.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":30783,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":30783,"derivative":{"underlying":"American Depository Shares","underlying_shares":30783},"source":{"system":"sec-edgar","filing":"0000950170-24-013266","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017024013266/ownership.xml","form_type":"4"}},{"id":1651375,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2024-02-09T21:15:20.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":3.87,"expiration_date":"2034-02-08","underlying":"American Depository Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-24-013266","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017024013266/ownership.xml","form_type":"4"}},{"id":1799525,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T20:09:35.000Z","date":"2023-08-18","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.195,"value":29875.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 48,333 shares represent restricted stock units."}],"balance_after":76667,"source":{"system":"sec-edgar","filing":"0001628280-23-030224","document":"wk-form4_1692734960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828023030224/wk-form4_1692734960.xml","form_type":"4"}},{"id":1855670,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T20:59:30.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":51667,"source":{"system":"sec-edgar","filing":"0001628280-23-022091","document":"wk-form4_1686776347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828023022091/wk-form4_1686776347.xml","form_type":"4"}},{"id":1877804,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T22:43:26.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.7,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-013918","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924323013918/doc4.xml","form_type":"4"}},{"id":2111835,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T02:11:15.000Z","date":"2022-11-16","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-22-036301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924322036301/doc4.xml","form_type":"4"}},{"id":2111834,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T02:11:15.000Z","date":"2022-11-16","kind":"disposition_to_issuer","acquired":false,"shares":3141,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the \"Merger Agreement\"), by and among LogicBio Therapeutics, Inc. (the \"Company\"), Alexion Pharmaceuticals, Inc. (\"Parent\") and Camelot Merger Sub, Inc. (\"Merger Sub\"), on November 16, 2022 (the \"Effective Time\"), Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-036301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924322036301/doc4.xml","form_type":"4"}},{"id":2220987,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-27T20:16:39.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an annual grant of restricted stock units (\"RSUs\") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested RSUs."}],"balance_after":6667,"source":{"system":"sec-edgar","filing":"0001628280-22-018052","document":"wf-form4_165636098273574.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828022018052/wf-form4_165636098273574.xml","form_type":"4"}},{"id":2221883,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T20:35:55.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.09,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-024012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924322024012/doc4.xml","form_type":"4"}},{"id":2225148,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T12:20:00.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted by LogicBio Therapeutics, Inc. (the \"Company\") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-038242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919122038242/doc4.xml","form_type":"4"}},{"id":2609864,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-09T23:54:02.000Z","date":"2021-08-05","kind":"grant","acquired":true,"shares":71186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date."}],"balance_after":71186,"derivative":{"exercise_price":17,"expiration_date":"2031-08-04","underlying":"Common Stock","underlying_shares":71186},"source":{"system":"sec-edgar","filing":"0001209191-21-050488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919121050488/doc4.xml","form_type":"4"}},{"id":2669866,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T00:00:30.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.59,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919121040426/doc4.xml","form_type":"4"}},{"id":2686069,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T21:03:34.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":6000,"price":9.5,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":6000,"derivative":{"exercise_price":9.5,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-21-011545","document":"wf-form4_162266780108629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828021011545/wf-form4_162266780108629.xml","form_type":"4"}},{"id":2821362,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-02T19:00:59.000Z","date":"2021-02-26","kind":"exercise","acquired":false,"shares":10108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options vested and became exercisable on February 9, 2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options vested and became exercisable on February 9, 2016."}],"balance_after":0,"derivative":{"exercise_price":26.98,"underlying":"Common Stock","underlying_shares":10108},"source":{"system":"sec-edgar","filing":"0001209191-21-016479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919121016479/doc4.xml","form_type":"4"}},{"id":2821361,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T19:00:59.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":19021,"price":130.11,"value":2474822.31,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":2558,"source":{"system":"sec-edgar","filing":"0001209191-21-016479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919121016479/doc4.xml","form_type":"4"}},{"id":2821360,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-02T19:00:59.000Z","date":"2021-02-26","kind":"exercise","acquired":true,"shares":10108,"price":26.98,"value":272713.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon exercise of a stock option award."}],"balance_after":21579,"source":{"system":"sec-edgar","filing":"0001209191-21-016479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919121016479/doc4.xml","form_type":"4"}},{"id":2925239,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-05T00:00:09.000Z","date":"2021-01-01","kind":"exercise","acquired":false,"shares":3141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3141},"source":{"system":"sec-edgar","filing":"0001209191-21-000517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919121000517/doc4.xml","form_type":"4"}},{"id":2925238,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T00:00:09.000Z","date":"2021-01-01","kind":"exercise","acquired":true,"shares":3141,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."}],"balance_after":3141,"source":{"system":"sec-edgar","filing":"0001209191-21-000517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919121000517/doc4.xml","form_type":"4"}},{"id":3076363,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-24T16:36:21.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":2558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":11471,"source":{"system":"sec-edgar","filing":"0001209191-20-043610","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919120043610/doc4.xml","form_type":"4"}},{"id":3101749,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-24T00:00:11.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":3141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."}],"balance_after":3141,"derivative":{"underlying":"Common Stock","underlying_shares":3141},"source":{"system":"sec-edgar","filing":"0001209191-20-038659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919120038659/doc4.xml","form_type":"4"}},{"id":3101748,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-24T00:00:11.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the options will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of LogicBio Therapeutics, Inc. (the \"Company\") 2021 Annual Meeting of Stockholders, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan (the \"2018 Plan\")."}],"balance_after":10000,"derivative":{"exercise_price":7.96,"expiration_date":"2030-06-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-038659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919120038659/doc4.xml","form_type":"4"}},{"id":3113111,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T12:28:56.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":3427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":3427,"derivative":{"exercise_price":8.69,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":3427},"source":{"system":"sec-edgar","filing":"0001628280-20-009236","document":"wf-form4_159187851570790.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828020009236/wf-form4_159187851570790.xml","form_type":"4"}},{"id":3333743,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-21T01:00:19.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":10869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders."}],"balance_after":10869,"derivative":{"exercise_price":12.65,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":10869},"source":{"system":"sec-edgar","filing":"0001209191-19-061664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000120919119061664/doc4.xml","form_type":"4"}},{"id":3449661,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-08-02T16:25:42.000Z","date":"2019-07-31","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10108,"derivative":{"exercise_price":26.98,"exercise_date":"2016-02-09","expiration_date":"2025-02-09","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-19-044255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119044255/doc4.xml","form_type":"4"}},{"id":3449660,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T16:25:42.000Z","date":"2019-07-31","kind":"sale","acquired":false,"shares":5000,"price":117.93,"value":589650.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 29, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock."}],"balance_after":8913,"source":{"system":"sec-edgar","filing":"0001209191-19-044255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119044255/doc4.xml","form_type":"4"}},{"id":3449659,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-02T16:25:42.000Z","date":"2019-07-31","kind":"exercise","acquired":true,"shares":2500,"price":26.98,"value":67450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon exercise of a stock option award."}],"balance_after":13913,"source":{"system":"sec-edgar","filing":"0001209191-19-044255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119044255/doc4.xml","form_type":"4"}},{"id":3455320,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-26T17:01:55.000Z","date":"2019-07-25","kind":"grant","acquired":true,"shares":2801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":11413,"source":{"system":"sec-edgar","filing":"0001209191-19-043380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119043380/doc4.xml","form_type":"4"}},{"id":3567987,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-02T23:59:57.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":6854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger."}],"balance_after":6854,"derivative":{"exercise_price":18.66,"expiration_date":"2029-03-13","underlying":"Common Stock","underlying_shares":6854},"source":{"system":"sec-edgar","filing":"0000899243-19-009669","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924319009669/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-14"}},{"id":3567986,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-02T23:59:57.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":70324,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Reporting Person's stock option to acquire 740,000 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (\"X4\") on March 13, 2019 (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on August 22, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":70324,"derivative":{"exercise_price":10.44,"expiration_date":"2028-08-21","underlying":"Common Stock","underlying_shares":70324},"source":{"system":"sec-edgar","filing":"0000899243-19-009669","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924319009669/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-14"}},{"id":3595293,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-03-15T01:31:33.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":70324,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Reporting Person's stock option to acquire 740,000 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (\"X4\") on March 13, 2019 (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on August 22, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":70324,"derivative":{"exercise_price":10.44,"expiration_date":"2028-08-21","underlying":"Common Stock","underlying_shares":70324},"source":{"system":"sec-edgar","filing":"0000899243-19-007824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924319007824/doc4.xml","form_type":"4"}},{"id":3623607,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-01T17:34:28.000Z","date":"2019-02-28","kind":"sale","acquired":false,"shares":500,"price":96,"value":48000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":8612,"source":{"system":"sec-edgar","filing":"0001209191-19-015127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919119015127/doc4.xml","form_type":"4"}},{"id":3785801,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-23T01:13:29.000Z","date":"2018-10-18","kind":"grant","acquired":true,"shares":24102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, October 18, 2018."}],"balance_after":24102,"derivative":{"exercise_price":10,"expiration_date":"2028-10-17","underlying":"Common Stock","underlying_shares":24102},"source":{"system":"sec-edgar","filing":"0000899243-18-027213","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000089924318027213/doc4.xml","form_type":"4"}},{"id":3829708,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-30T17:26:19.000Z","date":"2018-08-28","kind":"sale","acquired":false,"shares":2468,"price":74.85,"value":184729.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Column 4 were effected to cover anticipated tax liabilities arising out of stock compensation.  The reporting person adopted a Rule 10b5-1 Trading Plan pursuant to which these sales would have occurred on or about July 27, 2018 but due to administrative error the sales did not occur as initially planned."}],"balance_after":9112,"source":{"system":"sec-edgar","filing":"0001209191-18-048986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919118048986/doc4.xml","form_type":"4"}},{"id":3859184,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2018-07-30T19:46:51.000Z","date":"2018-07-26","kind":"grant","acquired":true,"shares":3230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service."}],"balance_after":3230,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3230},"source":{"system":"sec-edgar","filing":"0001209191-18-044485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919118044485/doc4.xml","form_type":"4"}},{"id":3859183,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-30T19:46:51.000Z","date":"2018-07-26","kind":"grant","acquired":true,"shares":606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":11580,"source":{"system":"sec-edgar","filing":"0001209191-18-044485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919118044485/doc4.xml","form_type":"4"}},{"id":3883967,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T18:11:07.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.55,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-18-029843","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118029843/doc1.xml","form_type":"4"}},{"id":3892225,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-06-15T12:17:17.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the \"Company's\") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company."}],"balance_after":12500,"derivative":{"exercise_price":11.14,"exercise_date":"2019-06-14","expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-18-003020","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000156218018003020/primarydocument.xml","form_type":"4"}},{"id":3937284,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-11T16:48:43.000Z","date":"2018-05-10","kind":"sale","acquired":false,"shares":7402,"price":51.533,"value":381447.266,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.16 to $51.795, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":10974,"source":{"system":"sec-edgar","filing":"0001209191-18-029603","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919118029603/doc4.xml","form_type":"4"}},{"id":4248576,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2017-07-31T17:25:39.000Z","date":"2017-07-27","kind":"grant","acquired":true,"shares":5273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service."}],"balance_after":5273,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5273},"source":{"system":"sec-edgar","filing":"0001209191-17-046749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919117046749/doc4.xml","form_type":"4"}},{"id":4248575,"issuer":{"id":56619,"kind":"organization","name":"EXACT SCIENCES CORP","symbol":"EXAS"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-31T17:25:39.000Z","date":"2017-07-27","kind":"grant","acquired":true,"shares":791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy."}],"balance_after":18376,"source":{"system":"sec-edgar","filing":"0001209191-17-046749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124140/000120919117046749/doc4.xml","form_type":"4"}},{"id":4277194,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2017-06-19T20:04:40.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the option shares vest on the first anniversary of the date of grant (the \"Vesting Date\"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a \"Change in Control\" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement."}],"balance_after":12500,"derivative":{"exercise_price":14.37,"exercise_date":"2018-06-15","expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-17-002290","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000156218017002290/primarydocument.xml","form_type":"4"}},{"id":4295565,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T16:54:29.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.3,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-17-023613","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117023613/doc1.xml","form_type":"4"}}]}